Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1219 ARTÍCULOS , VIENDO DEL 46 AL 60

Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity

Smith LM, Strittmatter SM.

Cold Spring Harb Perspect Med. 2017 May 1;7(5):a024075. doi: 10.1101/cshperspect.a024075.

Genomic variants, genes, and pathways of Alzheimer's disease: An overview

Naj AC, Schellenberg GD; Alzheimer's Disease Genetics Consortium (ADGC).

Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):5-26. doi: 10.1002/ajmg.b.32499.

Deep Brain Stimulation for Alzheimer's Disease: Ethical Challenges for Clinical Research

Siegel AM, Barrett MS, Bhati MT.

J Alzheimers Dis. 2017;56(2):429-439. doi: 10.3233/JAD-160356.

Hypoxia/ischemia activate processing of Amyloid Precursor Protein: impact of vascular dysfunction in the pathogenesis of Alzheimer's disease

Salminen A, Kauppinen A, Kaarniranta K.

J Neurochem. 2017 Feb;140(4):536-549. doi: 10.1111/jnc.13932. Epub 2017 Jan 9.

NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease

Husain MA, Ur Rehman S, Sarwar T, Ishqi HM, Tabish M.

Curr Cancer Drug Targets. 2017;17(5):467-478. doi: 10.2174/1568009616666161216093403.

Role of ABC transporters in the pathology of Alzheimer's disease

Zhao Y, Hou D, Feng X, Lin F, Luo J.

Rev Neurosci. 2017 Feb 1;28(2):155-159. doi: 10.1515/revneuro-2016-0060.

Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease

Ashok BS, Ajith TA, Sivanesan S.

Clin Exp Pharmacol Physiol. 2017 Mar;44(3):327-334. doi: 10.1111/1440-1681.12717.

Orexin and Alzheimer's Disease

Liguori C.

Curr Top Behav Neurosci. 2017;33:305-322. doi: 10.1007/7854_2016_50.

Inflammasome activation and innate immunity in Alzheimer's disease

Heneka MT.

Brain Pathol. 2017 Mar;27(2):220-222. doi: 10.1111/bpa.12483.

Targeted Nanoparticles for the Treatment of Alzheimer's Disease

Martín-Rapun R, De Matteis L, Ambrosone A, Garcia-Embid S, Gutierrez L, de la Fuente JM.

Curr Pharm Des. 2017;23(13):1927-1952. doi: 10.2174/1381612822666161226151011.

Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?

Whyte LS, Lau AA, Hemsley KM, Hopwood JJ, Sargeant TJ.

J Neurochem. 2017 Mar;140(5):703-717. doi: 10.1111/jnc.13935. Epub 2017 Jan 23.

Dietary patterns, Alzheimer's disease and cognitive decline: recent insights

Koch M, Jensen MK.

Curr Opin Lipidol. 2017 Feb;28(1):79-80. doi: 10.1097/MOL.0000000000000376.

Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy

Finke JM, Banks WA.

Hum Antibodies. 2017;25(3-4):131-146. doi: 10.3233/HAB-160306.

The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study

Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, Marino S, Putignano S.

J Alzheimers Dis. 2017;56(2):557-565. doi: 10.3233/JAD-160808.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias